Cyclo Therapeutics Inc Stock Price, News & Analysis

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) will participate in the 30th Annual NNPDF Family Support & Medical Conference from July 28-31, 2022, in Orlando, FL. The company aims to engage with the Niemann-Pick disease community, showcasing its Trappsol® Cyclo™ IV formulation for treating Niemann-Pick Disease Type C (NPC). Key presentations include a discussion on July 30 at 1:30 PM ET and an overview of its clinical program on July 31 at 8:45 AM ET. For more details, visit the conference website.

Cyclo Therapeutics (Nasdaq: CYTH) announced that Dr. Lise Kjems will present at the World Orphan Drug Congress USA 2022 from July 11-13, 2022, in Boston, MA. Her talk, titled From Bench to Bedside - A Review of the Trappsol Cyclo Program for the Treatment of Niemann Pick Disease Type C, is scheduled for July 13 at 3:45 PM ET. The session will cover the company’s Trappsol® Cyclo™ formulation and its clinical program targeting this rare genetic disease. The presentation will be available on the company's website following the event.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that Professor Caroline Hastings, MD, will present at the 2022 NPC Conference on June 23-24, 2022. Dr. Hastings will discuss the proprietary formulation Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C. The session includes updates from Phase I and II studies and the launch of the Phase III pivotal TransportNPC trial. The conference aims to address the urgent need for treatments for NPC patients globally. A live webcast will be available for registered attendees.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that CEO N. Scott Fine will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022 in Miami, FL, and virtually. Management will be available for one-on-one meetings with registered investors. A video webcast of the presentation will be available on demand starting May 24, 2022, at 7:00 AM ET. Cyclo Therapeutics focuses on developing medicines for rare diseases.

Cyclo Therapeutics (CYTH) reported Q1 2022 financial results, including a net loss of approximately $2.8 million. The company is advancing its lead program, Trappsol® Cyclo™, in a pivotal Phase 3 study for Niemann-Pick Disease Type C1 (NPC1) and plans to initiate a Phase 2 study for Alzheimer's Disease this year. Recent collaborations with the University of the Witwatersrand aim to expand the use of Trappsol® Cyclo™. Research and development expenses decreased by 67% to $1.1 million, while prepaid clinical expenses rose by $1.4 million. Cash reserves stand at $11.8 million.

Cyclo Therapeutics (NASDAQ: CYTH) will participate in a Virtual Investor Niemann-Pick Disease Type C (NPC) Spotlight event on May 16, 2022, at 2:00 PM ET. The company will discuss NPC, a rare genetic disorder and the development of Trappsol® Cyclo™, a treatment showing promising results in clinical studies. Key executives will join Professor Caroline Hastings, the Global Principal Investigator for the ongoing TransportNPC™ study. Cyclo Therapeutics has received Orphan Drug Designation for Trappsol® Cyclo™ in the U.S. and EU.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced its participation in the Virtual Investor Alzheimer’s Disease Spotlight event on April 5, 2022, at 1:00 PM ET. The company's management, including CEO N. Scott Fine and CMO Lise Lund Kjems, will engage in a fireside chat with key opinion leader Cynthia A. Lemere, PhD. Cyclo Therapeutics will discuss its Trappsol® Cyclo™ program for Alzheimer’s treatment, which has recently received FDA clearance for a Phase 2 study targeting early Alzheimer’s disease. The webcast will also be available for replay.

Cyclo Therapeutics (NASDAQ: CYTH) announced a research collaboration with the University of the Witwatersrand in Johannesburg to explore its proprietary Trappsol® Cyclo™ platform technology. This partnership will enhance the development of Cyclo's ongoing Phase 3 study for Niemann-Pick Disease Type C and a planned Phase 2 study for early Alzheimer’s disease. The agreement aims to advance scientific knowledge and expand Cyclo's intellectual property estate. The collaboration emphasizes the strategic importance of leveraging Wits' research capabilities for innovative therapeutic applications.

Cyclo Therapeutics, a clinical-stage biotechnology company, announced its participation in the 2022 Virtual Growth Conference hosted by Maxim Group from March 28-30, 2022. Key executives, including N. Scott Fine and Lise Lund Kjems, will engage in a live fireside chat on March 30 at 12:30 PM ET. The conference will cover various sectors and feature extensive investor interactions. Cyclo Therapeutics is developing Trappsol® Cyclo™ for Niemann-Pick Disease Type C, with ongoing clinical trials and plans for Alzheimer's research.